Growth Hormone Secretagogues: Ipamorelin vs CJC-1295
A comparative analysis of two prominent growth hormone secretagogues used in research settings.
Growth hormone secretagogues (GHS) represent a class of compounds that stimulate the secretion of growth hormone from the pituitary gland. Among the most studied in research settings are Ipamorelin and CJC-1295, each with distinct mechanisms and pharmacokinetic profiles.
Ipamorelin: Selective GH Release
Ipamorelin is a pentapeptide that acts as a selective agonist of the ghrelin/GHS receptor (GHS-R1a). Its key distinguishing feature in research is its selectivity — it stimulates GH release without significantly elevating cortisol, prolactin, or ACTH levels, which are common side effects observed with other GHS compounds like GHRP-6.
CJC-1295 with DAC
CJC-1295 is a synthetic analogue of GHRH (Growth Hormone-Releasing Hormone). The addition of the Drug Affinity Complex (DAC) technology dramatically extends its half-life by enabling it to bind to albumin in the bloodstream. This pharmacokinetic modification makes it suitable for research protocols requiring sustained GH elevation.
This article is intended for research and educational purposes only.
Disclaimer: This article is for informational and educational purposes only. It does not constitute medical advice. All research peptides discussed are intended for laboratory use only and are not approved for human consumption.